The characteristics of “high cost” and “high uncertainty” of innovative drugs pose significant challenges to public health insurance payment mechanisms. Internationally, Managed Entry Agreements (MEA) are currently the main tool to address the uncertainty of the clinical effectiveness of innovative drugs. The United Kingdom started exploring MEA relatively early. The core mechanism involves conditional payment and standardized data collection and evidence generation, fully leveraging real-world evidence to link drug prices with actual clinical effectiveness, ultimately achieving value-oriented payment alignment. This study provides an in-depth analysis of the institutional framework, core elements, and application scenarios of the UK MEA, offering a reference for exploring innovative payment pathways for high-value innovative drugs in China and supporting the strategic purchasing of medical insurance aimed at maximizing value.
Key words
managed entry agreements /
innovative payment /
real-world evidence /
international experience
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] World Health Organization Regional Office for Europe. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research[R]. Copenhagen: WHO Regional Office for Europe, 2015:68.
[2] 蒙代尔·图米,希蒙·雅罗斯瓦夫斯基.高值药品市场准入协议:从方案设计到医保定价的国际经验[M].陈怡,吴晶,译.北京:清华大学出版社,2025:13.
[3] National Institute for Health and Care Excellence. Managed access[EB/OL].[2026-01-26]. https://www.nice.org.uk/what-nice-does/patient-access-schemes-and-pricing-agreements/managed-access.
[4] TRIGG L A, BARNISH M S, HAYWARD S, et al.An analysis of uncertainties and data collection agreements in the Cancer Drugs Fund[J]. Pharmacoecon open, 2024, 8(2): 303-311.
[5] National Institute for Health and Care Excellence. Data collection agreement[EB/OL].[2026-01-26]. https://www.nice.org.uk/what-nice-does/our-guidance/about-technology-appraisal-guidance/data-collection-agreement.
[6] National Institute for Health and Care Excellence. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma[EB/OL]. (2018-07-13)[2026-01-26].https://www.nice.org.uk/guidance/ta524.
[7] National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under[EB/OL]. (2024-05-15)[2026-01-26].https://www.nice.org.uk/guidance/ta975.
[8] National Institute for Health and Care Excellence. Nusinersen for treating spinal muscular atrophy[EB/OL].(2019-07-24)[2026-01-26].https://www.nice.org.uk/guidance/ta588/chapter/2-Information-about-nusinersen.
[9] NHS England.100,000 patients receive early access to latest cancer therapies on NHS[EB/OL]. (2024-03-30)[2026-01-26].https://www.england.nhs.uk/2024/03/100000-patients-receive-early-access-to-latest-cancer-therapies-on-nhs/.
[10] UK Parliament. Innovative Medicines Fund - Question for Department of Health and Social Care[EB/OL]. (2025-03-26)[2026-01-26]. https://questions-statements.parliament.uk/written-questions/detail/2025-03-26/41684/.
[11] 吕兰婷,王知.真实世界证据在高值创新药附条件支付中的应用——以英国癌症药物基金和创新药物基金为例[J].中国医疗保险, 2026(2): 42-46.
[12] 国家医疗保障局办公室.关于开展真实世界医保综合价值评价试点工作的通知[EB/OL].(2025-09-23)[2026-01-26].https://www.nhsa.gov.cn/art/2025/9/23/art_109_17984.html.
[13] 肖梦丽,赵迎盼,邱攀博,等.“以患者为中心”的药物研发患者体验数据收集探讨[J].中国新药杂志,2025,34(20):2199-2202.
